Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
A panel of the Ministry of Health, Labor and Welfare (MHLW) on January 29 gave the final thumbs-up for a plan to add shingles vaccines to the national immunization program (NIP), beginning in FY2025. The NIP access will start on…
To read the full story
Related Article
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
May 25, 2023
- MHLW to Resume Discussions on Revising Basic Immunization Plan
March 27, 2023
REGULATORY
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…